Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Journal of Managed Care & Specialty Pharmacy|December 29, 2022
Inconsistencies in the days supply values reported in pharmacy claims databases for biologics with long maintenance intervalsChang Xu, Shannon A Ferrante, Timothy Fitzgerald, et al.
Heliyon|November 28, 2022
Genetic algorithm shape optimization to manipulate the nonlinear response of a clamped-clamped beamTushar Mollik, Ying Geng, Md Raf E Ul Shougat, et al.
Dermatology and Therapy|February 25, 2022
Characteristics of New Biologic Users Among the Moderate-to-Severe Psoriasis Population-Retrospective Cohort Study Leveraging the Modernizing Medicine Data Services DatabaseTimothy Fitzgerald, Aimee M Near, Hyunchung Kim, et al.
Headache|October 31, 2018
Health care Resource Utilization and Migraine Disability Along the Migraine Continuum Among Patients Treated for MigraineStephen D Silberstein, Lulu Lee, Kavita Gandhi, et al.
Dermatology and Therapy|March 19, 2022
Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USADominic Pilon, Timothy Fitzgerald, Maryia Zhdanava, et al.
Current Medical Research and Opinion|April 10, 2020
Real-world 2-year treatment patterns among patients with psoriatic arthritis treated with injectable biologic therapiesJessica A Walsh, Qian Cai, Iris Lin, et al.
The Journal of Dermatological Treatment|February 24, 2026
On-label persistence in psoriasis after switching to guselkumab, tumor necrosis factor inhibitors, interleukin-17 inhibitors, or apremilast from other advanced therapiesMaryia Zhdanava, Timothy Fitzgerald, Porpong Boonmak, et al.
Dermatology and Therapy|March 17, 2023
Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USATimothy Fitzgerald, Maryia Zhdanava, Dominic Pilon, et al.
Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine|September 25, 2014
Predictors of adherence to glaucoma treatment in a multisite studyPaul F Cook, Sarah J Schmiege, Steven L Mansberger, et al.
Biologics : Targets & Therapy|January 14, 2021
Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator InfliximabTimothy Fitzgerald, Richard Melsheimer, Marie-Hélène Lafeuille, et al.
Pageof 4